Synthesis, Structural Characterization and Anticancer Evaluation of 2-Aminobenzothiazole Derivative via Benzoyl Isothiocyanate

2-Aminobenzothiazole derivatives are well-established scaffolds in medicinal chemistry, valued for their diverse pharmacological profiles. In this study, a novel synthetic route led to the development of N-(1,3-benzothiazol-2-yl)benzamide (SIBO), whose structure was thoroughly characterized via FTIR, NMR, HRMS and SC-XRD techniques. The experimentally determined crystal geometry was further supported by DFT calculations at the B3LYP/6-31G(d,p) level, showing excellent agreement in bond parameters and a moderate HOMO–LUMO energy gap indicative of potential bioactivity. Hirshfeld surface analysis highlighted key intermolecular interactions contributing to the stability of the crystal lattice. Preliminary in vitro cytostatic screening against MDA-MB-231 and MCF-7 breast cancer cell lines revealed dose-dependent growth inhibition, with SIBO reducing MDA-MB-231 cell viability by up to 52% at 10 µg/mL. Although its efficacy was lower to that of standard adriamycin, the selective activity and structural simplicity of SIBO indicate its potential as a lead compound for the development of safer and tailored anticancer drugs.